Ensysce BiosciencesENSC
13F holders, Q1 2026 (March 31)15holders −2
4new positions
7sold out
1famous investor
$0.54avg. 13F price*
At the end of Q1 2026, 15 institutions reported holding Ensysce Biosciences Inc. (ENSC) in their 13F filings, down 2 from Q4 2025. 4 opened new positions and 7 sold out. The largest holders were Adage Capital Partners Gp, L.L.C. ($81K), Perceptive Advisors LLC ($47K) and Geode Capital Management, LLC ($40K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Ensysce Biosciences Inc.
- CUSIP
- 293602504
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $58K |
| Exits | 7 | $171K |
All 13F filers, Q4 2025 → Q1 2026: 170,930 shares bought and 186,540 shares sold, net −15,610 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Adage Capital Partners Gp, L.L.C. | 0.00% | No change | 149,711 | $81K |
| Perceptive Advisors LLC | 0.00% | No change | 86,666 | $47K |
| Geode Capital Management, LLC | 0.00% | Add +234.4% | 73,880 | $40K |
| Citadel Advisors | 0.00% | New | 57,363 | $31K |
| XTX Topco Ltd | 0.00% | New | 24,363 | $13K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 23,854 | $13K |
| Jane Street Group, LLC | 0.00% | New | 13,570 | $7K |
| Tru Independence Asset Management 2, LLC | 0.00% | Add +8.3% | 13,000 | $7K |
| Virtu Financial LLC | 0.00% | New | 13,313 | $7K |
| Vanguard Capital Management LLC | 0.00% | — | 12,854 | $7K |
| UBS Group AG | 0.00% | Add +8691.0% | 8,791 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +14.6% | 6,094 | $3K |
| FNY Investment Advisers, LLC | 0.00% | No change | 3,000 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Add +15.4% | 486 | $262 |
| BlackRock, Inc. | 0.00% | No change | 65 | $35 |
"% of holder's portfolio" is ENSC's weight in each manager's 13F, not the share of Ensysce Biosciences Inc. the manager owns.